Literature DB >> 16984606

Ganciclovir and the treatment of Epstein-Barr virus hepatitis.

Leon A Adams1, Bastiaan Deboer, Gary Jeffrey, Richard Marley, George Garas.   

Abstract

Epstein-Barr virus (EBV) is part of the herpesvirus family that infects up to 90% of the population. Initial infection is often subclincal in children but will generally result in symptomatic infectious mononucleosis in adolescents and adults. Ganciclovir has been utilized in immunocompromised patients with EBV encephalitis and post-liver transplant for EBV fulminant hepatitis. Herein, the successful use of ganciclovir in two immunocompetent patients with severe EBV hepatitis is reported.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16984606     DOI： 10.1111/j.1440-1746.2006.03257.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN： 0815-9319            Impact factor:   4.029


  9 in total

1.  Acute hepatitis due to epstein-barr virus in an immunocompetent patient.

Authors:  Neha Pagidipati; Keith L Obstein; Rachel Rucker-Schmidt; Robert D Odze; Christopher C Thompson
Journal:  Dig Dis Sci       Date:  2009-05-21       Impact factor: 3.199

2.  Fever and Jaundice in a Previously Healthy Teenager.

Authors:  Daphne S Say; Juan Chaparro; Jeffrey L Koning; Mamata Sivagnanam
Journal:  Clin Pediatr (Phila)       Date:  2016-10       Impact factor: 1.168

3.  Severe EBV hepatitis treated with valganciclovir.

Authors:  R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi
Journal:  Infection       Date:  2012-07-27       Impact factor: 3.553

Review 4.  Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group.

Authors:  Jessica L Mellinger; Lorenzo Rossaro; Willscott E Naugler; Satish N Nadig; Henry Appelman; William M Lee; Robert J Fontana
Journal:  Dig Dis Sci       Date:  2014-01-25       Impact factor: 3.199

Review 5.  Infectious diseases and the liver.

Authors:  Rohit Talwani; Bruce L Gilliam; Charles Howell
Journal:  Clin Liver Dis       Date:  2011-02       Impact factor: 6.126

6.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  Cryptogenic colitis due to occult cytomegalovirus infection.

Authors:  Daniel J B Marks; Philip J Smith; Farooq Z Rahman; Robert F Miller; Jonathan A Ledermann; Stuart L Bloom
Journal:  Frontline Gastroenterol       Date:  2010-09-28

8.  High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections.

Authors:  Dominik Olszewski; Fanny Georgi; Luca Murer; Vardan Andriasyan; Fabien Kuttler; Anthony Petkidis; Robert Witte; Artur Yakimovich; Lucy Fischer; Alina Rozanova; Yohei Yamauchi; Gerardo Turcatti; Urs F Greber
Journal:  Sci Data       Date:  2022-10-08       Impact factor: 8.501

9.  Infectious mononucleosis hepatitis in young adults: two case reports.

Authors:  Min-Jung Kang; Tae-Hun Kim; Ki-Nam Shim; Sung-Ae Jung; Min-Sun Cho; Kwon Yoo; Kyu Won Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.